Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Eur J Intern Med ; 19(7): 531-6, 2008 Nov.
Article in English | MEDLINE | ID: mdl-19013383

ABSTRACT

BACKGROUND: Thyroid-Associated Orbitopathy (TAO) is an autoimmune disease characterized by orbital inflammation involving both adipose tissue and extra-ocular muscles (EOM). Whereas bilateral and possibly asymmetric orbital involvement is commonly found at radiological work-up, mono-orbital involvement is poorly documented, and ascribed to an initial and/or transient stage of subsequent bilateral TAO. METHODS: From a cohort of two hundred TAO patients, we selected retrospectively fourteen patients with initial clinical unilateral TAO. Five of them were excluded because of clinical bilateralization. RESULTS: The sex ratio was 0.8 (4M, 5F), and mean age 44.6 years (range: 18-63). All patients were euthyroid when the initial magnetic resonance imaging (MRI) was performed. One patient was treated with Levothyroxine, because of subclinical hypothyroidism. Eight patients (six smokers) suffered from Graves' disease, of 1-4 years duration, for which they were treated with antithyroid drugs. A thyroidectomy was performed in two patients. None of the patients ever received radioiodine. Six patients remained euthyroid after stopping of the antithyroid regimen, and two became hypothyroid. Seven patients had active, and two severe TAO. Four of nine patients exhibited bilateralization of TAO on initial MRI. Clinical status ultimately improved or normalized in all. In two patients, MRI performed after 9 years demonstrated partial shrinkage of previously enlarged EOMs, together with fatty involution of involved muscles. CONCLUSIONS: Unilateral TAO is not different and just as severe as bilateral TAO. At initial work-up MRI shows signs of bi-laterality in 45% (4/9), with mild involvement of 1 or 2 extra-ocular muscles. The radiological status of affected muscles does not normalize, even in the very long term.


Subject(s)
Graves Ophthalmopathy/pathology , Magnetic Resonance Imaging , Orbital Diseases/pathology , Adipose Tissue/pathology , Adolescent , Adult , Aged , Antithyroid Agents/therapeutic use , Databases, Factual , Female , Follow-Up Studies , Graves Ophthalmopathy/drug therapy , Humans , Male , Middle Aged , Oculomotor Muscles/pathology , Orbital Diseases/drug therapy , Recovery of Function , Young Adult
2.
Br J Ophthalmol ; 89(6): 724-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15923509

ABSTRACT

BACKGROUND/AIM: Thyroid associated orbitopathy (TAO) and Graves' disease (GD) have an autoimmune pathogenesis, possibly related to the thyrotropin receptor (TSHR). The aim of this study was to determine whether TSHR immunoreactivity is correlated with disease severity or serum TSHR antibody (TRAB) levels. METHODS: Orbital tissues from 30 patients with TAO were compared with those of 20 patients with strabismus and four with non-thyroid orbital inflammation. TSHR was detected by immunohistochemistry and TRAB were measured by radioreceptor assay. RESULTS: No TSHR immunoreactivity was detected in the 24 control orbital tissues, whereas in all TAO biopsies elongated fibroblast-like cells, expressing TSHR, were present. These cells were located between the muscle cells, which were separated by oedema in the acute phase but fibrous tissue in the chronic phase of disease. Semi-thin sections showed numerous mast cells present in the chronic phase and in close contact with adipocytes. The number of TSHR immunostained cells was high in early disease, decreased with disease duration, and was positively correlated with TRAB levels at the onset of TAO. CONCLUSION: TSHR immunoreactivity was demonstrated specifically in TAO orbits which highlights the importance of TRAB early in the pathogenesis.


Subject(s)
Autoimmune Diseases/metabolism , Graves Disease/metabolism , Oculomotor Muscles/metabolism , Orbital Diseases/metabolism , Receptors, Thyrotropin/metabolism , Adult , Aged , Aged, 80 and over , Autoantibodies/blood , Autoimmune Diseases/immunology , Autoimmune Diseases/pathology , Biopsy , Disease Progression , Female , Graves Disease/immunology , Graves Disease/pathology , Humans , Immunoenzyme Techniques , Male , Middle Aged , Oculomotor Muscles/pathology , Orbit/metabolism , Orbit/pathology , Orbital Diseases/immunology , Receptors, Thyrotropin/immunology , Severity of Illness Index , Thyroiditis, Autoimmune/immunology , Thyroiditis, Autoimmune/metabolism , Thyroiditis, Autoimmune/pathology
3.
Thyroid ; 15(3): 205-9, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15785239

ABSTRACT

Peroxiredoxin 5 (PRDX5) is a newly discovered thioredoxin peroxidase able to reduce peroxides that is implicated in antioxidant protective mechanisms. We report here its expression in the human thyroid gland. Twenty-seven human thyroid specimens were examined by immunohistochemistry. They included six normal thyroid tissues, five multinodular goiters, nine hot nodules, two Hürthle cell adenomas, and five thyroids from patients with Graves' disease. In the control tissue, PRDX5 expression was heterogeneous, being stronger in cubical functionally active follicular cells than in flat quiescent thyrocytes. It was diffuse in the cytoplasm, occasionally localized in inclusions that most likely corresponded to mitochondria. This feature was particularly marked in the Hürthle cell adenoma case. In multinodular goiters, hot nodules, and Graves' thyroids, the cytosolic labeling was enhanced compared to the control tissue and a signal was also detected in few nuclei. To determine whether the level of expression was different between multinodular goiters and hyperthyroid Graves' thyroids, PRDX5 immunoblotting was performed in these two respective tissues. We observed that PRDX5 expression was higher in the thyroid gland of patients with Graves' disease compared to multinodular goiters. In conclusion, our data show that PRDX5 is expressed in the thyroid gland where it could act as antioxidant. The level of expression is directly correlated with the functional status of epithelial cells, being higher in multinodular goiters, and even more pronounced in hyperthyroid tissues, such as Graves' disease.


Subject(s)
Peroxidases/genetics , Thyroid Gland/physiology , Adenoma, Oxyphilic/enzymology , Adenoma, Oxyphilic/genetics , Adenoma, Oxyphilic/pathology , Gene Expression Regulation, Enzymologic , Graves Disease/genetics , Graves Disease/pathology , Humans , Hyperthyroidism/enzymology , Hyperthyroidism/genetics , Immunohistochemistry , Peroxidases/metabolism , Peroxiredoxins , Thyroid Gland/cytology , Thyroid Gland/pathology
4.
Eur J Intern Med ; 14(5): 321-325, 2003 Aug.
Article in English | MEDLINE | ID: mdl-13678758

ABSTRACT

BACKGROUND: Thyroid nodules in patients with Graves' disease (GD) are common, and the incidence of coexisting thyroid carcinoma is a much debated subject, which is addressed in this study. METHODS: In order to determine the incidence rate of coexisting malignancy, a retrospective study was conducted on 103 patients who underwent surgery for GD between 1990 and 2000 at the Cliniques Universitaires Saint-Luc in Brussels, Belgium. The patients were classified into groups. Those in group I had a solitary palpable nodule (4.9%), those in group II multiple palpable nodules (12.6%), group IIIa had nodule(s) revealed by imaging techniques (incidentalomas: 17.5%), and group IIIb had diffuse non-nodular goiter (65%). RESULTS: Patients with nodules (groups I, II, and IIIa) were found to have significantly more thyroid carcinomas than those with diffuse non-nodular goiters (P=0.02), and the rate of malignancy was significantly increased when the nodules were palpable (groups I and II; P=0.03). Eight patients (7.8%) were diagnosed as having coexisting carcinomas, all but one being microcarcinomas. CONCLUSIONS: Well-differentiated papillary carcinomas are found to coexist with GD surgically treated (7.8%) and occur most frequently in GD with palpable nodular lesions (35%). Even though the majority (88%) of coexisting carcinomas are microcarcinomas, the presence of palpable nodules justifies further evaluation and follow-up.

5.
Acta Chir Belg ; 102(5): 323-7; discussion 327-8, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12471764

ABSTRACT

BACKGROUND: The authors report their initial experience with partial and total thyroidectomy, and neck exploration for hyperparathyroidism using the video-assisted approach. PATIENTS AND METHODS: Between June 1999 and March 2001, 114 patients underwent a thyroid (n = 57) or parathyroid (n = 57) operation using a video-assisted cervical approach. Video-assisted neck exploration was conducted in all cases under general anaesthesia leading to a partial or total thyroidectomy, and to a selective adenoma removal in PHPT or to a subtotal parathyroid resection in SHPT. RESULTS: IN THE THYROID GROUP: The mean cranio-caudal and transversal diameter of the resected specimen were respectively 4.9 +/- 0.9 and 2.8 +/- 0.6 cm, and mean total lobar weight was 11.7 +/- 5.8 g. Conversion to conventional surgery was required in 5 patients (8.8%). The mean operative time was 133.9 +/- 26.9 and 86.5 +/- 22.5 minutes for total and partial thyroidectomy respectively. The laryngeal nerve was identified in 96% of cases. The mean length of skin incision was 24.0 +/- 2 mm. There were 3 cases of postoperative hypocalcemia, and 2 cases of postoperative hoarseness. The postoperative hospital stay was less than 24 hours for 72.7% of patients. The pain intensity at day one (VAS) was 2.1 +/- 1.3. IN THE PARATHYROID GROUP: Seven of the 44 patients who underwent PHPT (15.9%) and 4 of the 13 patients who underwent surgery for SHPT (30.8%) were converted to a conventional surgical technique. The mean operative time in PHPT and SHPT was 47.3 +/- 22.3 minutes and 136.8 +/- 18.7 minutes, respectively. Recurrent laryngeal nerve was identified in 53.1% of the patients. The median diameter and weight of the resected parathyroid glands were 1.5 cm (range 0.8-2.7) and 0.9 g (range 0.5-7), respectively. The length of skin incision was 24 +/- 2 mm. All but 2 patients are currently cured. Postoperative complications included hematoma and transient hoarseness each in one patient (1.75%). The median pain intensity at day one (VAS) was 0.5 (range: 0 to 3.6). In the PHPT group, the postoperative hospital stay was less than 24 hours for 56.7% of the patients, and less than 48 hours for 91.9% of them. CONCLUSION: The video-assisted approach for thyroid and parathyroid surgery is feasible, safe and effective in selected cases. Benefits for the patients should be further assessed in future prospective comparative trials.


Subject(s)
Parathyroidectomy , Thyroidectomy , Video-Assisted Surgery , Follow-Up Studies , Humans , Parathyroid Diseases/surgery , Parathyroidectomy/methods , Thyroid Diseases/surgery , Thyroidectomy/methods , Time Factors
6.
Acta Clin Belg ; 57(3): 148-53, 2002.
Article in French | MEDLINE | ID: mdl-12212356

ABSTRACT

The aim of this study was to report the clinical characteristics of 13 patients with Hürthle carcinoma. In the vast majority of them, disease was suspected by a palpable thyroid nodule. The results of preoperative examination (scintigraphy, ultrasonography, thyroglobulin) are also discussed as well as the pathological aspects and follow-up characteristics after total thyroidectomy.


Subject(s)
Adenoma, Oxyphilic/pathology , Thyroid Neoplasms/pathology , Adenoma, Oxyphilic/diagnosis , Adenoma, Oxyphilic/surgery , Adult , Aged , Female , Humans , Male , Middle Aged , Thyroid Neoplasms/diagnosis , Thyroid Neoplasms/surgery , Thyroidectomy
SELECTION OF CITATIONS
SEARCH DETAIL
...